“CSL has two main divisions,” said Raymond. “Let me break them into two parts:
- Behring (75% of profit) provides plasma-derived products (which treat blood clots, immune deficiency disorders etc) and operates plasma collection networks through CSL Plasma.
- Seqirus (25% of profit) manufactures and distributes non-plasma products such as influenza vaccines.
“The FY22 results were softer than the market expectation, mostly due to Behring division, which suffered from plasma collection constraint. It’s good to hear CSL suggested the plasma collection is now back to pre-COVID level,” Raymond said.
“CSL management has confirmed a return to growth in FY23, guiding 6% to 11%.
“We think this is conservative and also excludes last year’s acquisition of Vifor,” Raymond concluded.
CSL Limited (CSL)
Important: This content has been prepared without taking account of the objectives, financial situation or needs of any particular individual. It does not constitute formal advice. Consider the appropriateness of the information in regards to your circumstances.
